Professional
Added to YB: 2026-06-12
Pitch date: 2026-05-16
IMNM [bullish]
Immunome, Inc.
-12.57%
current return
Author Info
No bio for this author
Company Info
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Market Cap
$2.1B
Pitch Price
$21.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.55
P/E
-7.74
EV/Sales
368.03
Sector
Biotechnology
Category
growth
Aristotle Large Cap Growth New Position: Immunome, Inc.
IMNM (new position): Biotech led by ex-Seagen founder Clay Siegall. Lead drug Varegacestat for desmoid tumors posted positive Phase 3 data; FDA filing pending, launch late 2026/early 2027. Desmoid market peak $500-700M. 3 clinical-stage candidates + preclinical pipeline. $600M+ pro forma cash.
Read full article (1 min)